SmartCella Holding AB
Christian Kinch is a seasoned executive with extensive experience in leadership roles across various companies. Currently serving as Chairman of the Board and Founder at both SmartCella Holding AB and Swib Holding since 2015 and 2014 respectively, Christian has also held significant positions at Bactiguard AB from 2005 until May 2024, where responsibilities included Chairman of the Board and Vice Chairman. Prior experience includes founding and leading Netpharma, a company sold to IVAX Pharmaceuticals, from 1998 to 2004, and Kinchard Consulting, sold to Pharmexx, from 1994 to 1998. Christian’s career began at Roche as a Läkemededelskonsulent from 1992 to 1994. Christian graduated from the Stockholm School of Economics in 1992.
This person is not in the org chart
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.